secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2022-03-25T23:59:59+00:00
Accession:  0001816590-22-000014
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

COMPASS Pathways establishes The Centre for Mental Health Research and Innovation with King's College London and SLaM
--------------------------------------------------------------------------------

- Up to £12M investment over 10-year term; Centre to accelerate psychedelic therapy research and new care models.
- Initial focus on COMP360 psilocybin therapy for TRD, PTSD, and anorexia nervosa; expects 650-700 patients over 5 years.
- Facilities to be built at Bethlem Royal Hospital in London; state-of-the-art clinical trial space.
- Partnership with UK's largest NHS mental health trust (SLaM) and King's College London's IoPPN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000181659022000014/0001816590-22-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000181659022000014/cmps-20220324.htm
  HTML page:      https://secwatch.observer/filing/0001816590-22-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer